Today's Hours: 8:00am - 10:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Book
    edited by Eric Hollander, Randi J. Hagerman, Casara Jean Ferretti.
    Summary: "More than 40 years after the official recognition of infantile autism in DSM-III, advances continue to be made in our understanding of the possible causes, assessment and evaluation, and treatment of autism spectrum disorder (ASD). With contributions by dozens of experts in the field, this second edition of the Textbook of Autism Spectrum Disorders has been updated to reflect the latest research in ASD. Unrivaled in its thoroughness, this volume discusses issues of assessment and evaluation; examines the etiology of ASD and its recognized associations with other medical conditions; analyzes standard and experimental treatments; and delves into social policy issues pertinent to individuals with ASD and those who treat them. With summary points in each chapter and copious lists of recommended readings, this is an indispensable resource for psychiatrists, psychologists, neurologists, social workers, speech therapists, educators, and all others in the continuum of care"-- Provided by publisher.

    Contents:
    Cover
    Half Title
    Title
    Copyright
    Contents
    Contributors List
    Foreword
    PART I: Assessment, Evaluation, and Target Symptoms
    Part 1A: AASSESSMENT AND EVALUATION
    1 Epidemiology
    2 Psychiatric Assessment and Treatment
    3 Pediatric and Neurological Assessments
    4 Gender Dysphoria, Gender Incongruence, and Sexual Identity
    5 Racial and Ethnic Disparities in Assessment and Evaluation
    6 Digital Biomarkers in Diagnostics and Monitoring
    Part 1B: TARGET AND COMORBID SYMPTOMS
    7 Social Communication
    8 Diet and Nutrition
    PART II: Causes
    Part IIA: OVERVIEW 9 Genetics and Genomics
    10 Epigenomics
    11 Prenatal, Perinatal, and Parental Risk Factors
    12 Animal Models
    13 Electrophysiological Studies
    14 Environmental Toxicity and Immune Dysregulation
    Part IIB: SYNDROMIC CAUSES
    15 Overview of Syndromic Causes of ASD and Commonalities in Neurobiological Pathways
    16 Fragile X Syndrome and Associated Disorders
    17 Tuberous Sclerosis Complex
    18 16p11.2 and Other Recurrent Copy Number Variants Associated With ASD Susceptibility
    19 Rett Syndrome
    20 Prader-Willi Syndrome
    Part IIC: IMAGING AND ANATOMY 21 Neuroanatomical Findings
    22 The Amygdala in ASD
    23 Neurobiology of ASD Informed by Structural Imaging Research
    24 Positron Emission Tomography
    25 Functional Magnetic Resonance Imaging
    PART III: Treatments and Interventions
    Part IIIA: STANDARD PHARMACOLOGICAL TREATMENTS
    26 Serotonergic Medication
    27 Antipsychotics
    28 Treating Hyperactivity in Children With Pervasive Developmental Disorders
    Part IIIB: EXPERIMENTAL THERAPEUTICS
    29 Complementary and Integrative Approaches
    30 Oxytocin
    31 Vasopressin
    32 N-Acetylcysteine 33 Arbaclofen: From Animal Models to Clinical Trials
    34 Cannabis, Cannabinoids, and Immunomodulatory Agents
    Part IIIC: BEHAVIORAL AND EDUCATIONAL INTERVENTIONS
    35 Behavioral Treatments
    36 Early Start Denver Model
    37 The Developmental, Individual Difference, Relationship-Based Intervention Model: A Comprehensive Parent-Mediated Approach
    38 School-Based Interventions
    39 Language and Communication: Challenges and Treatments
    Part IIID: FUTURE TREATMENT DEVELOPMENTS
    40 Transcranial Magnetic Stimulation
    41 Stem Cell and Gene Therapy 42 Gene Therapy and Molecular Interventions
    PART IV: Consortiums, Employment, and Advocacy
    43 Consortiums
    Developing Precision Medicine Approaches to ASD
    Autism Biomarkers Consortium for Clinical Trials
    Interactive Autism Network
    44 Autism Strengths and Neurodiversity
    45 Role of Patient Advocacy Groups in Treatment Development
    Index
    Plates
    Back Cover
    Digital Access ProQuest Ebook Central 2022
  • Article
    Gallagher TJ, Civetta JM, Kirby RR.
    Crit Care Med. 1978 Sep-Oct;6(5):323-6.
    The term, optimal PEEP, requires redefinition in the light of new clinical data. With the onset of acute respiratory failure heralded by blood gas evidence of decreased oxygenation, PEEP is supplied in quantities sufficient to restore intrapulmonary shunt (Qsp/Qt) to a preselected goal of 15%. This is compatible with published criteria defining adequate blood gas exchange. Now rather than permitting reduction of cardiac output to be the end point of PEEP application, selective cardiovascular interventions to support preload, contractility, or afterload are made as appropriate so that cardiac function may be maintained until the preselected endpoint of shunt reduction of 15% can be made.
    Digital Access Access Options
  • Journal
    Digital Access Full text via HathiTrust, 1st (1870)-